RADNOR, Pa., Nov. 03, 2016 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and other neuropsychiatric disorders, today provided a business update and announced its financial results for the third quarter ended September 30, 2016. "We have made significant progress in advancing our status epilepticus program supported by our new intravenous formulation of ganaxolone," commented Christopher M. Cashman, chief executive officer of Marinus Pharmaceuticals. "With the identification of dose levels of ganaxolone IV that we believe to be safe and efficacious, we are preparing to initiate a Phase 2 study in patients suffering from this life-threatening seizure disorder. Additionally, we are expanding the clinical development of ganaxolone into postpartum depression where there is a significant unmet need and a strong mechanistic rationale for a therapeutic benefit from ganaxolone treatment." Status Epilepticus (SE)Marinus recently completed its Phase 1 dose-escalation study with ganaxolone IV in 36 healthy subjects. The study was designed to determine the pharmacokinetics, pharmacodynamics, and safety of ganaxolone IV administered as an ascending bolus or continuous infusion dose. Every dose regimen of ganaxolone IV administered, either bolus or continuous infusion, was generally safe and well tolerated. In addition, ganaxolone IV achieved dose levels targeted for efficacy in patients with SE and other indications. Marinus is preparing to commence a Phase 2 clinical trial in patients with SE in the first half of 2017. PostPartum Depression (PPD)Marinus plans to initiate a Phase 2 clinical trial in patients with PPD next year. PPD is a mood disorder that affects about 15% of women within the first year of childbirth. Common symptoms include feelings of extreme sadness, hopelessness, suicidal ideation, anxiety, and fatigue. PPD is thought to be linked to the rapid fluctuations in the levels of reproductive hormones and allopregnanolone (allo) after childbirth. Treatment with ganaxolone, which is a one-carbon analog of allo, may provide benefit to women suffering from PPD. Rare Genetic Seizure and Behavior Disorders in ChildrenThe anxiety and seizure benefits of ganaxolone were recently reported in two phase 2 exploratory studies in children with Fragile X Syndrome and females with PCDH19 genetic epilepsy. Marinus is currently enrolling patients with CDKL5 disorder (CDKL5) and Lennox-Gastaut Syndrome (LGS) in a Phase 2 study and expects data from these additional patient populations in mid-2017. Upon completion of these additional patients, and based upon the clinical data seen in all the studies conducted in children with rare genetic seizure and behavior disorders, Marinus intends to nominate one or more indications to progress to more advanced clinical studies. Third Quarter Financial Update At September 30, 2016, the Company had cash, cash equivalents and investments of $37.1 million, compared to $57.7 million at December 31, 2015. The Company believes that its cash, cash equivalents and investments, as of September 30, 2016, are adequate to fund operations into the second half of 2018.